Next-generation fusion company SHINE Technologies and WARF Therapeutics, a drug discovery programme from the Wisconsin Alumni Research Foundation (WARF), announced on Thursday promising pre-clinical research results from collaborative efforts with the Advanced Radiotheranostics Lab at the University of Wisconsin-Madison.

The studies showed that WT-7695 and ART-101, treatments that uses Ilumira, SHINE's non-carrier added lutetium-177 (Lu-177) chloride, have the potential to increase life span and be more effective in treating kidney and prostate cancer, respectively.

Partnering with UW-Madison and Morgridge Institute for Research Principal Investigators, WARF Therapeutics creates a translational research path that draws on research and an industry-focused approach to improve value propositions of drug candidates.

WARF Therapeutics has invested to accelerate the development of theranostic radiopharmaceutical programs at UW-Madison, like WT-7695 and ART-101, while SHINE Technologies provides the lutetium-177 integral to this innovative cancer treatment approach.